Leerink Partners Increases KalVista Pharmaceuticals (NASDAQ:KALV) Price Target to $20.00

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) had its target price boosted by equities researchers at Leerink Partners from $18.00 to $20.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has an "outperform" rating on the specialty pharmaceutical company's stock. Leerink Partners' price objective suggests a potential upside of 32.80% from the stock's previous close.

KALV has been the subject of a number of other reports. Jones Trading reaffirmed a "buy" rating and issued a $30.00 price objective on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $24.14.

KalVista Pharmaceuticals Stock Performance

Shares of KALV stock traded up $3.08 during trading hours on Monday, hitting $15.06. 11,288,769 shares of the company were exchanged, compared to its average volume of 535,359. KalVista Pharmaceuticals has a fifty-two week low of $7.30 and a fifty-two week high of $16.37. The company has a 50 day simple moving average of $12.39 and a two-hundred day simple moving average of $11.04. The firm has a market cap of $748.78 million, a P/E ratio of -4.05 and a beta of -0.04.

Insider Transactions at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,776 shares of the business's stock in a transaction on Monday, May 19th. The shares were sold at an average price of $11.84, for a total transaction of $32,867.84. Following the completion of the sale, the insider directly owned 106,611 shares in the company, valued at approximately $1,262,274.24. The trade was a 2.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Venrock Healthcare Capital Par purchased 25,000 shares of the company's stock in a transaction dated Wednesday, April 9th. The stock was purchased at an average price of $9.42 per share, for a total transaction of $235,500.00. Following the completion of the purchase, the insider owned 5,303,985 shares in the company, valued at approximately $49,963,538.70. The trade was a 0.47% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 15,899 shares of company stock valued at $206,176 in the last three months. 10.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in KALV. Goldman Sachs Group Inc. boosted its stake in shares of KalVista Pharmaceuticals by 3.7% in the first quarter. Goldman Sachs Group Inc. now owns 339,936 shares of the specialty pharmaceutical company's stock worth $3,923,000 after acquiring an additional 12,263 shares during the period. Rhumbline Advisers grew its holdings in KalVista Pharmaceuticals by 3.4% during the 1st quarter. Rhumbline Advisers now owns 52,918 shares of the specialty pharmaceutical company's stock valued at $611,000 after buying an additional 1,762 shares in the last quarter. Woodline Partners LP raised its position in shares of KalVista Pharmaceuticals by 25.5% during the first quarter. Woodline Partners LP now owns 1,617,469 shares of the specialty pharmaceutical company's stock valued at $18,666,000 after buying an additional 329,068 shares during the last quarter. Parkman Healthcare Partners LLC purchased a new position in shares of KalVista Pharmaceuticals in the first quarter worth $8,698,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of KalVista Pharmaceuticals by 13.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company's stock worth $281,000 after acquiring an additional 2,939 shares during the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.